Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 831-838

  Iwama, Tatsuaki ^a,b   Horie, Kazutaka ^a   Yoshikawa, Toshiaki ^a   Nobuoka, Daisuke ^a   Shimomura, Manami ^a   Sawada, Yu ^a   Nakatsura, Tetsuya ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Cytotoxic T lymphocyte epitope; Glypican 3; Hepatocellular carcinoma; Mouse

Indexed keywords

EPITOPE; GAMMA INTERFERON; GLYPICAN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; CANCER VACCINE; GLYPICAN; H 2KB PROTEIN, MOUSE; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; HISTOCOMPATIBILITY ANTIGEN H 2D(B); HISTOCOMPATIBILITY ANTIGEN H-2D(B); PEPTIDE FRAGMENT; SUBUNIT VACCINE; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TARGET CELL; ANIMAL; C57BL MOUSE; IMMUNOLOGY; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; GLYPICANS; H-2 ANTIGENS; IMMUNOTHERAPY; INTERFERON-GAMMA; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

MLCS; MLOWN;

EID: 84873666983     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1793     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Yamamoto J, Okada S, Shimada K, et al: Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 34: 707-713, 2001. (Pubitemid 32927994)
3. Greten TF, Manns MP and Korangy F: Immunotherapy of hepatocellular carcinoma. J Hepatol 45: 868-878, 2006. (Pubitemid 44646691)
4. Motomura Y, Senju S, Nakatsura T, et al: Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 66: 2414-2422, 2006.
5. Mizukoshi E, Nakamoto Y, Arai K, et al: Comparative analysis of various tumor-associated antigen-specific T-cell responses in patients with hepatocellular carcinoma. Hepatology 53: 1206-1216, 2011.
6. Butterfield LH, Ribas A, Dissette VB, et al: A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12: 2817-2825, 2006.
7. Greten TF, Forner A, Korangy F, et al: A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 10: 209, 2010.
8. Butterfield LH, Ribas A, Meng WS, et al: T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9: 5902-5908, 2003. (Pubitemid 38018074)
9. Nakatsura T, Yoshitake Y, Senju S, et al: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306: 16-25, 2003. (Pubitemid 36629398)
10. Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65: 6245-6254, 2005. (Pubitemid 40994410)
11. Filmus J: Glypicans in growth control and cancer. Glycobiology 11: R19-R23, 2001.
12. Filmus J, Capurro M and Rast J: Glypicans. Genome Biol 9: 224, 2008.
13. Komori H, Nakatsura T, Senju S, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
14. Nakatsura T, Komori H, Kubo T, et al: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 10: 8630-8640, 2004. (Pubitemid 40053431)
15. Sawada Y, Sakai M, Yoshikawa T, Ofuji K and Nakatsura T: A glypican-3-derived peptide vaccine against hepatocellular carcinoma. Oncoimmunology 1: 1448-1450, 2012.
16. Sawada Y, Yoshikawa T, Nobuoka D, et al: Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 18: 3686-3696, 2012.
17. Nobuoka D, Yoshikawa T, Takahashi M, et al: Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother: Nov 11, 2012 (Epub ahead of print).
18. Motomura Y, Ikuta Y, Kuronuma T, et al: HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 32: 985-990, 2008.
19. Koike K, Moriya K, Iino S, et al: High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19: 810-819, 1994. (Pubitemid 24109339)
20. Moriya K, Yotsuyanagi H, Shintani Y, et al: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78: 1527-1531, 1997. (Pubitemid 27343089)
21. Ikuta Y, Hayashida Y, Hirata S, et al: Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Sci 100: 132-137, 2009.
22. Wu X, Xu X, Gu R, et al: Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays. Autoimmunity 45: 176-185, 2012.
23. Nakatsugawa M, Horie K, Yoshikawa T, et al: Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. Int J Oncol 39: 1041-1049, 2011.
24. Hofmann UB, Voigt H, Andersen MH, Straten PT, Becker JC and Eggert AO: Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur J Immunol 39: 1419-1424, 2009.
25. Zhou X, Glas R, Momburg F, Hammerling GJ, Jondal M and Ljunggren HG: TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes. Eur J Immunol 23: 1796-1801, 1993. (Pubitemid 23236769)
26. Stuber G, Leder GH, Storkus WT, et al: Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 24: 765-768, 1994. (Pubitemid 24076647)
27. Tsukahara T, Kawaguchi S, Torigoe T, et al: HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med 7: 44, 2009.
28. Yoshikawa T, Nakatsugawa M, Suzuki S, et al: HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 102: 918-925, 2011.
29. Yamazoe S, Tanaka H, Iwauchi T, et al: Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Pancreas 40: 896-904, 2011.
30. Guo Y, Zhu Y and Sun S: Identification and functional studies of HLA-A0201 restricted CTL epitopes in the X protein of hepatitis B virus. Acta Virologica 55: 107-115, 2011.